Greater Combined Reductions of HbA 1c  ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators.

Autor: Dungan KM; Division of Endocrinology, Diabetes and Metabolism, The Ohio State University, 1581 Dodd Drive, Columbus, OH 43210, USA. kathleen.dungan@osumc.edu., Bardtrum L; Novo Nordisk A/S, Søborg, Denmark., Christiansen E; Novo Nordisk A/S, Søborg, Denmark., Eliasson J; Novo Nordisk A/S, Søborg, Denmark., Mellbin L; Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden., Woo VC; Section of Endocrinology and Metabolism, University of Manitoba, Winnipeg, MB, Canada., Vilsbøll T; Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Herlev, Denmark.
Jazyk: angličtina
Zdroj: Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2023 Aug; Vol. 14 (8), pp. 1415-1425. Date of Electronic Publication: 2023 May 31.
DOI: 10.1007/s13300-023-01413-5
Abstrakt: Introduction: A post hoc analysis of the PIONEER 1-5 and 8 trials assessed the clinically relevant composite endpoints of HbA 1c (glycated haemoglobin) reduction ≥ 1% and body weight loss of ≥ 5% or ≥ 10% with orally administered semaglutide versus comparators.
Methods: In the PIONEER trials, people with type 2 diabetes were randomised to orally administered semaglutide versus placebo (PIONEER 1, 4, 5 and 8), empagliflozin (PIONEER 2), sitagliptin (PIONEER 3) and liraglutide (PIONEER 4) for 26-78 weeks. This analysis assessed the proportion of people achieving an HbA 1c reduction of ≥ 1% and body weight loss of ≥ 5% at week 26 and at end of treatment, and the proportion of people achieving an HbA 1c reduction of ≥ 1% and body weight loss of ≥ 10% at end of treatment.
Results: Overall, 3506 people in PIONEER 1-5 and 8 were included. At week 26 and at end of treatment, odds of achieving the composite endpoint of an HbA 1c reduction of ≥ 1% and body weight loss of ≥ 5% were significantly greater with orally administered semaglutide 14 mg than with placebo (PIONEER 1, 4, 5 and 8; all p < 0.0001), empagliflozin 25 mg (PIONEER 2, p < 0.0001), sitagliptin 100 mg (PIONEER 3, p < 0.0001) and liraglutide 1.8 mg (PIONEER 4, p < 0.0001). Odds of achieving the composite endpoint of HbA 1c reduction of ≥ 1% and body weight loss of ≥ 10% at end of treatment were also significantly greater with orally administered semaglutide versus comparators.
Conclusion: In PIONEER 1-5 and 8, odds of achieving clinically relevant reductions in both HbA 1c and body weight were significantly greater with orally administered semaglutide versus comparators.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje